Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a US-based precision oncology company, announced on Monday that it has named Yong Ben, M.D., MBA as its new director.

Dr Ben has more than 20 years of medical experience in academia and pharmaceutical and biotech companies, including clinical practice, drug discovery and development in oncology and haematological malignancies. Currently, he is a venture partner at Eight Roads Venture (formerly known as Fidelity Ventures).

Previously, Dr Ben has served as chief medical officer, Solid Tumors at BeiGene, chief medical officer at BioAtla, global clinical leader of immuno-oncology clinical development at AstraZeneca. He started his career as a surgical oncologist at Peking Union Medical College Hospital.

Alan Holmer, chairman of the Corbus board of directors, said, 'Dr Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our board. Our recent license agreement for CRB-701 has helped cement our position as a precision oncology, and this appointment augments our board with extensive experience in oncology drug development in both the US and China. Dr Ben's more recent work in healthcare venture investment will add a unique perspective. We look forward to his contributions.'